Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSV-allo in acute respiratory failure due to COVID-19 pneumonia
2020-001682-36Phase 2Completed
- Sponsor
- CITOSPIN
- Start
- Apr 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, double-blind trial of MSV-allo in coronavirus pneumonia (2 arms), sponsored by CITOSPIN. Primary endpoint: Removal of invasive mechanical ventilation within 7 days. Started Apr 2020; status: completed.
02
Drugs
MSV-allo
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on 2020-001682-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001682-36.